About 619 million people worldwide live with low back pain, and it is the leading cause of years lived with disability (Cashin et al., JAMA, 2026). Most of it — about 90% — is nonspecific: pain without a single identifiable structural cause (Cashin et al., JAMA, 2026). Four major guidelines address that pain, and they agree on more than the internet suggests. The spine guideline is the North American Spine Society's 2020 guideline (Kreiner et al., The Spine Journal, 2020). The primary-care guideline is the American College of Physicians' 2017 guideline (Qaseem et al., Annals of Internal Medicine, 2017). The veterans guideline is the VA/DoD 2022 guideline. The current synthesis is a 2026 review in JAMA (Cashin et al., JAMA, 2026). There is no AMA low back pain guideline — attributions to one are misattributions of the ACP 2017 guideline. There is no standalone AAOS low back pain guideline — AAOS participated in the NASS 2020 guideline. What follows is what these four sources actually say, in one place.
The four guidelines
The NASS 2020 guideline is the spine-specific one: 82 clinical questions, more than 100 recommendations, covering adults with nonspecific back pain (Kreiner et al., The Spine Journal, 2020). It grades each recommendation — A means recommended, B means suggested, C means may be considered, I means the evidence is insufficient or conflicting. It excludes patients with a neurological deficit and leg pain below the knee. Those are separate pathways.
The ACP 2017 guideline is the primary-care one, written for the doctor a patient sees first (Qaseem et al., Annals of Internal Medicine, 2017). It separates acute and subacute pain from chronic pain and gives each its own first-line list.
The VA/DoD 2022 guideline is the veterans guideline, and it states a central point directly: no treatment is clearly superior to the others, so the choice is a shared decision between patient and clinician (VA/DoD, 2022).
The JAMA 2026 review synthesizes the World Health Organization, ACP, and NICE guidelines into one current picture (Cashin et al., JAMA, 2026). Acute pain is under 6 weeks, subacute is 6 to 12 weeks, chronic is over 12 weeks.
What they agree on
Movement first. Every guideline puts exercise and activity at the front of chronic back pain care. The ACP lists exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, motor control exercise, progressive relaxation, electromyography biofeedback, cognitive behavioral therapy, and spinal manipulation as first-line for chronic pain (Qaseem et al., Annals of Internal Medicine, 2017). The VA/DoD guideline finds that many types of clinician-directed, structured exercise improve pain, disability, and function — aerobic, aquatic, mobility, motor control, Pilates, strength training, structured walking, tai chi — and notes that nearly every activity is beneficial (VA/DoD, 2022). The JAMA review puts exercise of any type first for chronic pain, alongside psychological therapies and combined multidisciplinary care (Cashin et al., JAMA, 2026).
Imaging only when it changes the plan. Routine imaging is not indicated for most patients (Cashin et al., JAMA, 2026). The VA/DoD guideline is specific about why: imaging does not improve outcomes without focal deficits or red flags, and early MRI increases the probability of surgery 13 times, along with opioid use, cost, pain scores, and work absence (VA/DoD, 2022). NASS grades the evidence on imaging in the absence of red flags as insufficient — and grades the evidence that imaging findings correlate with the presence of low back pain as insufficient as well (Kreiner et al., The Spine Journal, 2020). A scan that shows change does not, by itself, explain pain.
Mind and body together. The NASS guideline gives its Grade A — the recommended tier — to two combinations: cognitive behavioral therapy combined with physical therapy, recommended over physical therapy alone to improve pain over 12 months, and treatments targeting fear of movement combined with physical therapy, recommended over physical therapy alone to improve pain in the first six months (Kreiner et al., The Spine Journal, 2020). It also grades psychosocial and workplace factors as worth assessing when counseling on the risk of acute pain becoming chronic. The VA/DoD guideline finds cognitive behavioral therapy modestly improves pain and function in chronic low back pain over 4 to 12 visits (VA/DoD, 2022).
Short courses of medication. When medication is wanted for acute or subacute pain, the ACP recommends an NSAID or a skeletal muscle relaxant (Qaseem et al., Annals of Internal Medicine, 2017). For chronic pain, NSAIDs are first if the non-drug measures are ineffective, then tramadol or duloxetine as second-line medication. NASS suggests non-selective NSAIDs and recommends against antidepressants for low back pain at Grade A (Kreiner et al., The Spine Journal, 2020). The VA/DoD summary puts the number needed to treat for NSAIDs at 6 — one in six patients gets at least 30% pain reduction over 4 to 12 weeks — and notes that beyond 12 weeks NSAIDs are no better than placebo (Buelt et al., American Family Physician, 2023).
Where they differ, or stay silent
Weight. Obesity is a risk factor for back pain (Cashin et al., JAMA, 2026). That is where the agreement ends. NASS grades the evidence that body mass index predicts recurrence of low back pain as insufficient, and the evidence that smoking or obesity predicts conversion from acute to chronic pain as insufficient (Kreiner et al., The Spine Journal, 2020). NASS makes no weight-loss recommendation for back pain anywhere in its guideline. The VA/DoD guideline makes no weight or body mass index recommendation either, and states plainly that no specific diet or supplement has evidence of benefit in low back pain (VA/DoD, 2022). No guideline prescribes weight loss as a back-pain treatment with a measured effect, and none sets a body mass index cutoff. Weight management belongs in comprehensive care alongside activity and conditioning — which is where it sits in the pre-surgery optimization conversation, not as a standalone prescription for pain.
Fusion. The NASS guideline finds insufficient evidence to make a recommendation for or against fusion for low back pain (Kreiner et al., The Spine Journal, 2020). That is the honest position: the guideline neither endorses nor rejects it for nonspecific pain. Fusion is considered for specific structural reasons — instability, deformity, stenosis with instability — never for nonspecific low back pain alone. The guideline's silence on fusion for nonspecific pain is consistent with that.
Injections. The BMJ 2025 guideline strongly recommends against corticosteroid or local anesthetic injection for chronic non-cancer spine pain (Busse et al., BMJ, 2025). The VA/DoD summary measured the effect of epidural steroid injections at an average improvement of 0.75 on a 10-point pain scale, with no benefit to function — an effect that may not be clinically relevant (VA/DoD, 2022). The VA/DoD summary also found radiofrequency ablation improved pain for up to 36 months without improving disability or quality of life; the BMJ guideline recommends against it (VA/DoD, 2022; Busse et al., BMJ, 2025). Facet joint injections were not beneficial compared with placebo. An epidural steroid injection has a place as a step in the pre-surgical pathway — where it sits, what a response means, when repeats stop, and the exit to surgery — not as a standalone treatment.
Vitamin D. NASS grades the evidence for vitamin D in low back pain as insufficient (Kreiner et al., The Spine Journal, 2020). The VA/DoD guideline states that vitamin D supplementation does not improve outcomes in low back pain (VA/DoD, 2022). It is an optimizable factor in pre-surgery preparation, not a treatment for the pain itself.
What it means in the exam room
Most back pain gets better with movement, time, and a short course of medication when needed. Acute pain is usually self-limited — about 72% recover by 12 months — while chronic pain is less favorable, with 42% recovering within 12 months (Cashin et al., JAMA, 2026). The guidelines agree that the first visit should establish three things: whether there are red flags or a neurological deficit that change the pathway, what the patient can do rather than what they must avoid, and what the plan is if the first measures do not work. Lumbar radiculopathy (sciatica) and lumbar stenosis account for about 5 to 10% of low back pain in primary care, and they follow their own pathways (Cashin et al., JAMA, 2026). The rest — the 90% that is nonspecific — is managed the way the guidelines describe: activity first, imaging only when it changes the plan, mind and body together, medication in short courses, and surgery only when there is a specific structural reason for it. A spinal fusion is never the answer to nonspecific pain alone.
Frequently asked questions
Is there an AMA guideline for back pain?
No. There is no American Medical Association low back pain guideline. Search results attributing one to the AMA are misattributions of the American College of Physicians 2017 guideline (Qaseem et al., Annals of Internal Medicine, 2017). The AMA-adjacent source is the 2026 JAMA review, which synthesizes the WHO, ACP, and NICE guidelines (Cashin et al., JAMA, 2026).
What is the best treatment for low back pain?
No treatment is clearly superior to the others — that is the VA/DoD guideline's central point, and the choice is a shared decision (VA/DoD, 2022). For chronic pain, every guideline puts exercise first: any type of structured, clinician-directed exercise, alongside psychological therapies such as cognitive behavioral therapy and combined multidisciplinary care (Cashin et al., JAMA, 2026). The treatment that works is the one the patient can sustain.
Should I get an MRI for my back pain?
Usually not, unless it changes the plan. Routine imaging is not indicated for most patients (Cashin et al., JAMA, 2026). Imaging does not improve outcomes without focal deficits or red flags, and early MRI increases the probability of surgery 13 times (VA/DoD, 2022). A herniated disc is diagnosed on MRI — history and examination raise the suspicion, the MRI confirms it — but for nonspecific back pain, the scan rarely changes what should happen next.
Show all questionsShow fewer questions7 more ▾
Do the guidelines recommend losing weight for back pain?
No guideline prescribes weight loss as a back-pain treatment with a measured effect, and none sets a body mass index cutoff. Obesity is a risk factor for back pain (Cashin et al., JAMA, 2026), but NASS grades the evidence that body mass index predicts recurrence as insufficient and makes no weight-loss recommendation (Kreiner et al., The Spine Journal, 2020). The VA/DoD guideline makes no weight recommendation and states that no specific diet has evidence of benefit in low back pain (VA/DoD, 2022). Weight management belongs in comprehensive care alongside activity and conditioning.
What medications do the guidelines recommend?
For acute or subacute pain, an NSAID or a skeletal muscle relaxant if medication is wanted (Qaseem et al., Annals of Internal Medicine, 2017). NSAIDs carry the medication evidence with a measured effect: one in six patients gets at least 30% pain reduction over 4 to 12 weeks (Buelt et al., American Family Physician, 2023). For chronic pain, NSAIDs are first if non-drug measures are ineffective, then tramadol or duloxetine second-line. Antidepressants are not recommended for low back pain (Kreiner et al., The Spine Journal, 2020). Acetaminophen performed no better than placebo. Opioids improve pain and function for up to 4 months; the long-term risks are high without proven benefit. Medication choices defer to the patient's pharmacist or primary care doctor.
Do the guidelines recommend fusion for back pain?
Not for nonspecific low back pain. The NASS guideline finds insufficient evidence to make a recommendation for or against fusion for low back pain (Kreiner et al., The Spine Journal, 2020). Fusion is considered for specific structural reasons — instability, deformity, stenosis with instability — never for nonspecific pain alone. The decision is framed by symptoms, examination, imaging, spinal stability, and treatment history.
Do epidural steroid injections help back pain?
The measured effect is small. The VA/DoD summary found epidural steroid injections improved pain by an average of 0.75 on a 10-point scale, with no benefit to function (VA/DoD, 2022). The BMJ 2025 guideline strongly recommends against corticosteroid injection for chronic non-cancer spine pain (Busse et al., BMJ, 2025). An injection has a place as a step in the pre-surgical pathway — where it sits, what a response means, when repeats stop, and the exit to surgery. Spinal-injection risks are reviewed in more depth with the pain management physician performing them.
What is cognitive behavioral therapy doing in a back pain guideline?
It is graded A in the NASS guideline — the recommended tier. Cognitive behavioral therapy combined with physical therapy is recommended over physical therapy alone to improve pain over 12 months, and treatments targeting fear of movement combined with physical therapy are recommended over physical therapy alone to improve pain in the first six months (Kreiner et al., The Spine Journal, 2020). Pain changes how people move, and how people move changes pain. The guideline treats that as medicine, not reassurance.
How long does back pain last?
Acute pain is usually self-limited: about 72% recover by 12 months (Cashin et al., JAMA, 2026). Chronic pain is less favorable, with 42% recovering within 12 months. Prior episodes of low back pain are a prognostic factor for pain becoming chronic, and psychosocial and workplace factors should be assessed when counseling on that risk (Kreiner et al., The Spine Journal, 2020). Recovery is measured in function — what the patient can do — not only in pain scores.
Which guideline should I read?
The NASS 2020 guideline is the spine-specific one, written for spine care (Kreiner et al., The Spine Journal, 2020). The ACP 2017 guideline is the primary-care one, written for the first doctor a patient sees (Qaseem et al., Annals of Internal Medicine, 2017). The JAMA 2026 review is the one to read first — it synthesizes the WHO, ACP, and NICE guidelines into one current picture (Cashin et al., JAMA, 2026). They agree on the essentials: move first, image only when it changes the plan, treat mind and body together, and keep medication courses short.